治疗压力下转移性癌症可操作基因组演化有限
该研究对231例转移性实体瘤患者的250对纵向活检样本进行全基因组测序,中位间隔6.4个月,期间接受标准治疗。结果显示标准治疗基因组生物标志物在99%的配对中完全一致,91%的患者第二次测序未发现额外临床试验入组标志物,提示单次转移灶全基因组测序通常足以识别标准治疗标志物和试验机会。
要点
- 标准治疗基因组生物标志物在首次与第二次活检间完全一致率达99%。
- 首次活检发现的219个临床试验入组标志物中,随访活检回收94%。
- 91%患者第二次全基因组测序未发现额外临床试验入组标志物。
核心结论
- 治疗后的转移灶可操作基因组演化有限,单次转移活检全基因组测序通常足以识别标准治疗基因组标志物和试验性治疗机会。
研究设计与样本
- 研究纳入231例成人转移性实体瘤患者,纵向收集250对活检样本进行全基因组测序,活检间隔中位6.4个月。
主要发现
- 标准治疗生物标志物可在23%的活检中识别,临床试验入组标志物可在72%的活检中识别。
- 标准治疗基因组生物标志物在99%的配对中首次与第二次活检完全一致。
- 首次活检识别的219个临床试验入组标志物中,94%在随访活检中回收。
- 91%的患者第二次全基因组测序未发现额外临床试验入组标志物。
- 小分子抑制剂或激素治疗靶向的特定基因演化频率较高,分别见于21%和22%的病例。
临床怎么用
- 对于接受标准治疗的转移性实体瘤患者,单次转移灶全基因组测序通常足以识别标准治疗基因组标志物和临床试验入组机会,无需常规重复测序。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Genomic profiling is critical for the identification of treatment options for patients with metastatic cancer, but it remains unclear how frequently this procedure should be repeated during the course of the disease. To address this, we analyzed whole-genome sequencing (WGS) data of 250 biopsy pairs, longitudinally collected over the treatment course of 231 adult patients with a representative variety of metastatic solid malignancies. Within the biopsy interval (median, 6.4 months), patients received one or multiple lines of (mostly) standard-of-care (SOC) treatments, with all major treatment modalities being broadly represented. SOC biomarkers and biomarkers for clinical trial enrollment could be identified in 23% and 72% of biopsies, respectively. For SOC genomic biomarkers, we observed full concordance between the first and the second biopsy in 99% of pairs. Of the 219 biomarkers for clinical trial enrollment that were identified in the first biopsies, we recovered 94% in the follow-up biopsies. Furthermore, a second WGS analysis did not identify additional biomarkers for clinical trial enrollment in 91% of patients. More-frequent genomic evolution was observed when considering specific genes targeted by small-molecule inhibitors or hormonal therapies (21% and 22% of cases, respectively). Together, our data demonstrate that there is limited evolution of the actionable genome of treated metastases. A single WGS analysis of a metastatic biopsy is generally sufficient to identify SOC genomic biomarkers and to identify investigational treatment opportunities.
引用
- van de Haar J, Hoes LR, Roepman P, et al. Limited evolution of the actionable metastatic cancer genome under therapeutic pressure. Nat Med. 2021. PMID: 34373653. doi:10.1038/s41591-021-01448-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。